As proof of concept that AVJ16 could be a useful tool in a clinically relevant setting, we compared the response to AVJ16 treatment of a human healthy lung organoid versus a human NSCLC organoid from a surgically resected tumor that expresses IGF2BP1. This evidence concerns the gene IGF2BP1 and neoplasm.